Health Care Related Organization – Page 21

Sanofi’s Beyfortus Achieves Blockbuster Status, Poised for Further Growth in US Market

5 months ago talkbio0Tagged Antibodies, Beyfortus, blockbuster sales, Growth, Infant, Market, Protection, Respiratory syncytial virus, sanofi, U.S.

Beyfortus, RSV antibody, Sanofi, blockbuster sales, US market growth, infant protection, respiratory syncytial virus

2025 J.P. Morgan Healthcare Conference: Optimism, Innovation, and Shifting Landscapes

5 months ago talkbio0Tagged Administration occupational activities, ambulatory care services, Aortic Valve Insufficiency, deal activity, digital health, expansion, Gene Modification, Health care facility, Pharmaceutical Services, regulatory environment, Transplant Registry Unified Management Program

AI in healthcare, outpatient care expansion, pharmaceutical services, regulatory environment, deal activity, digital health, gene editing, Trump administration

Abbott’s Spinal Cord Stimulation Systems Demonstrate Long-Term Efficacy in Chronic Pain Management

5 months ago talkbio0Tagged abbott, Approved, BurstDR, Chronic pain, Neurostimulation procedures of spinal cord tissue, non-surgical back pain, Stimulation procedure, Svalbard, United States Food and Drug Administration, XR

Abbott, spinal cord stimulation, chronic pain, BurstDR stimulation, Proclaim Plus, Proclaim XR, FDA approval, non-surgical back pain

Roche’s Itovebi Demonstrates Significant Overall Survival Benefit in Advanced Breast Cancer Study

5 months ago talkbio0Tagged Clinical Research, INAVO120, Inavolisib, Itovebi, Malignant neoplasm of breast, Overall Survival, PIK3CA mutation, Roche (company)

Itovebi, inavolisib, breast cancer, PIK3CA mutation, overall survival, INAVO120 study, Roche

Julie Kim to Succeed Christophe Weber as Takeda’s CEO in 2026

5 months ago talkbio0Tagged biopharmaceutical company, CEO, Christophe Weber, Drug Industry, Kim, Leadership, succession, Takeda, Transition Mutation

Takeda, Julie Kim, Christophe Weber, CEO succession, pharmaceutical industry, leadership transition, biopharmaceutical company

Enhertu Secures 7th FDA Approval for Expanded Use in HER2-Low and HER2-Ultralow Breast Cancer

5 months ago talkbio0Tagged Approved, AstraZeneca, Daiichi, Enhertu, HER2-low, Malignant neoplasm of breast, Sankyo, United States Food and Drug Administration

Enhertu, FDA Approval, HER2-Low, HER2-Ultralow, Breast Cancer, AstraZeneca, Daiichi Sankyo

Sage Therapeutics Rejects Biogen’s Acquisition Bid, Initiates Strategic Review

5 months ago talkbio0Tagged Acquisition, Biogen, Depression, Postpartum, Drug Industry, M&A, strategic alternatives, Zurzuvae

Sage Therapeutics, Biogen, acquisition rejection, strategic alternatives, ZURZUVAE, postpartum depression, pharmaceutical industry, M&A

Pfizer Agrees to $60 Million Settlement Over Nurtec Anti-Kickback Allegations

5 months ago talkbio0Tagged anti-kickback suit, Migraine Disorders, Nurtec, Pfizer, settlement

Pfizer, Nurtec, anti-kickback suit, settlement, Biohaven, migraine medicine

Bristol Myers Squibb and Pfizer Unveil Promising Colorectal Cancer Treatments at ASCO GI 2025

5 months ago talkbio0Tagged 2025, Braftovi, Cancer Therapeutic Procedure, Colorectal Carcinoma, Immunotherapy, Metastasis from malignant neoplasm of colon and/or rectum, Myers, Opdivo, Pfizer, squibb, Yervoy

Colorectal cancer, metastatic colorectal cancer, Bristol Myers Squibb, Pfizer, Opdivo, Yervoy, Braftovi, ASCO GI 2025, cancer treatment, immunotherapy.

Novo Nordisk’s Obesity Drug Breakthrough: 22% Weight Loss at Week 36 Boosts Stock by 11%

5 months ago talkbio0Tagged 22%, amycretin, Drug Industry, next-gen, Nordisk, Obesity, semaglutide, Stock Surge, Weight Loss

Novo Nordisk, Obesity drug, 22% weight loss, Stock surge, Next-gen obesity treatment, Amycretin, Semaglutide, Pharmaceutical industry